For this we used [11C]erlotinib, which is structurally identical to the epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor erlotinib, a clinically used drug for the treatment of non-small cell lung cancer. Here, EGFR is linked to non-small cell lung carcinoma.